Geron Corp GERN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:57 PM EDT
3.90quote price arrow down-0.10 (-2.38%)
Volume
4,604,745
52 week range
1.64 - 4.30
Loading...
  • Open3.96
  • Day High3.99
  • Day Low3.84
  • Prev Close4.00
  • 52 Week High4.30
  • 52 Week High Date04/29/24
  • 52 Week Low1.64
  • 52 Week Low Date03/13/24

Key Stats

  • Market Cap2.316B
  • Shares Out593.13M
  • 10 Day Average Volume9.45M
  • Dividend-
  • Dividend Yield-
  • Beta0.45
  • YTD % Change86.49

KEY STATS

  • Open3.96
  • Day High3.99
  • Day Low3.84
  • Prev Close4.00
  • 52 Week High4.30
  • 52 Week High Date04/29/24
  • 52 Week Low1.64
  • 52 Week Low Date03/13/24
  • Market Cap2.316B
  • Shares Out593.13M
  • 10 Day Average Volume9.45M
  • Dividend-
  • Dividend Yield-
  • Beta0.45
  • YTD % Change86.49

RATIOS/PROFITABILITY

  • EPS (TTM)-0.35
  • P/E (TTM)-11.27
  • Fwd P/E (NTM)-12.72
  • EBITDA (TTM)-209.532M
  • ROE (TTM)-60.04%
  • Revenue (TTM)519,999.981
  • Gross Margin (TTM)-
  • Net Margin (TTM)-38,729.81%
  • Debt To Equity (MRQ)23.99%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Geron Corp

 

Content From Our Affiliates

Profile

MORE
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical...
John Scarlett M.D.
Chairman of the Board, President, Chief Executive Officer
Andrew Grethlein Ph.D.
Executive Vice President, Chief Operating Officer
Michelle Robertson
Chief Financial Officer, Executive Vice President - Finance, Treasurer
Scott Samuels Esq.
Executive Vice President, Chief Legal Officer, Secretary
Melissa Behrs
Executive Vice President - Business Operations, Chief Alliance Officer
Address
919 East Hillsdale Boulevard, Suite 250
Foster City, CA
94404
United States

Top Peers

SYMBOLLASTCHG%CHG
VERA
Vera Therapeutics Inc
37.75-3.43-8.33%
CLDX
Celldex Therapeutics Inc
35.11+2.10+6.36%
RCKT
Rocket Pharmaceuticals Inc
23.02-0.09-0.37%
AGIO
Agios Pharmaceuticals Inc
47.82-1.01-2.07%
NTLA
Intellia Therapeutics Inc
22.94-0.15-0.65%